Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination HIV therapy with Nelfinavir and Saquinavir
NCT00001094Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nelfinavir and saquinavir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of patients with virologic success at 48 weeks. Status: withdrawn.
02
Drugs
nelfinavirsaquinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001094.